Martin Spahn, MD, from the University Hospital Bern, Bern, Switzerland, discusses the challenges of imaging modalities in oligometastatic prostate cancer at the European Association of Urology (EAU) conference 2017 in London, UK. Currently, especially with PSMA PET CT scans, the problem is standardisation of compounds. Every institution prepares and uses different compounds, which in turn affects how they are compared. He explains that the end result of standardising these modalities will be using the most effective treatment, and therefore improving patient outcomes.
